AstraZeneca - Latest News [Page 1]
AstraZeneca Welcomes Investment In Cancer Treatments
Tuesday, 25 June 2024, 4:56 am | AstraZeneca
The funding increase of $604 million over four years will allow Pharmac to review its priority list and deliver lifesaving and life changing medicines for New Zealanders. More >>
Astrazeneca Welcomes New Zealand Government’s Commitment To Pharmac
Monday, 29 April 2024, 4:29 pm | AstraZeneca
Ben McDonald, Country President of AstraZeneca Australia and New Zealand said he was pleased to see action. “This additional funding will help ensure New Zealanders have better access to innovative medicines, which could significantly improve their ... More >>
AstraZeneca Welcomes Gov Commitment To Improving Access To Medicines For NZers Living With Cancer And Rare Diseases
Wednesday, 1 June 2022, 4:00 pm | AstraZeneca
Auckland, 1st June, 2022 : AstraZeneca New Zealand welcomes today’s release of the Pharmac Review Final Report and the Government’s commitment to improving equity of access to life-saving cancer medicines and increasing investment in screening ... More >>
AstraZeneca Welcomes Provisional Consent For COVID-19 Vaccine In New Zealand
Thursday, 29 July 2021, 12:25 pm | AstraZeneca
AstraZeneca welcomes the announcement made by the New Zealand Government and regulatory authority Medsafe today that COVID-19 Vaccine AstraZeneca has been granted provisional consent for individuals 18 years and older. New Zealand secured 7.6 million doses ... More >>
International asthma clinical expert to visit NZ
Tuesday, 17 February 2009, 5:20 pm | AstraZeneca
World-renowned asthma researcher Professor Paul M O'Byrne will be in New Zealand between 18 – 24 February. More >>
Stark choice for around 640,000 Kiwis
Monday, 24 November 2008, 3:31 pm | AstraZeneca
Over a half a million older New Zealanders will soon face a stark medical choice - pay for a longstanding medicine that was previously funded, or accept a government-funded generic alternative produced in India. More >>
Breast Cancer Trails Herald Hope
Wednesday, 19 December 2007, 10:03 am | AstraZeneca
New results from one of the world’s largest breast cancer trails herald hope for thousands of women More >>
Hospital Supply in Jeopardy as negotiations stall
Tuesday, 31 July 2007, 2:48 pm | AstraZeneca
PHARMAC’s decision to issue a media statement about the ongoing negotiations with AstraZeneca over Betaloc CR and Plendil ER has confirmed AstraZeneca’s fear that negotiations with PHARMAC have broken down. More >>
NZ Australia gap widening in cholesterol control
Tuesday, 1 May 2007, 11:05 am | AstraZeneca
April, 2007 Recent data from an audit commissioned by pharmaceutical company AstraZeneca of 6,901 heart patients has shown that New Zealand patients with recorded high cholesterol levels and on a cholesterol reducing agent (statins i ) are at least twice as likely ... More >>
Alternative supply of adrenaline for New Zealand
Monday, 22 January 2007, 11:20 am | AstraZeneca
AstraZeneca has secured an approved source of adrenaline to meet the current shortage in New Zealand, General Manager Lance Gravatt said today. More >>
AstraZeneca finalises long-term Zoladex supply
Friday, 23 December 2005, 9:54 am | AstraZeneca
Pharmaceutical company AstraZeneca New Zealand Ltd today announced that it had finalised an agreement with the Pharmaceutical Management Agency of New Zealand (PHARMAC) for the long-term supply of its prostate and breast cancer medicine Zoladex®. More >>
AstraZeneca reaches agreement with PHARMAC
Monday, 19 December 2005, 4:54 pm | AstraZeneca
Pharmaceutical company AstraZeneca New Zealand Ltd today announced that it had reached a verbal agreement with the Pharmaceutical Management Agency of New Zealand (PHARMAC) to continue supplying its prostate and breast cancer medicine Zoladex® to the local ... More >>
Cancer medicine to be withdrawn due to subsidy cut
Thursday, 15 December 2005, 2:31 pm | AstraZeneca
Pharmaceutical company AstraZeneca Limited will withdraw its prostate and breast cancer drug Zoladex from the local market, following a funding cut by the Pharmaceutical Management Agency of New Zealand (PHARMAC). More >>
Breakthrough survival data on Arimidex® released
Monday, 12 December 2005, 11:10 am | AstraZeneca
Post-menopausal women with hormone-sensitive early breast cancer whose tamoxifen treatment is replaced with Arimidex (anastrozole), are likely to reduce their risk of dying by 29%, according to breakthrough new data released today at the San Antonio ... More >>
Top Breast Cancer Experts Share Knowledge In NZ
Monday, 22 August 2005, 11:50 am | AstraZeneca
Some of the world’s most eminent breast cancer experts will share their knowledge and experiences with New Zealanders for the first time in Auckland this November. More >>
Great news for breast cancer patients
Monday, 1 August 2005, 10:26 am | AstraZeneca
Early-stage breast cancer patients who are intolerant to tamoxifen have received great news with the announcement that Pharmac will increase funding of aromatase inhibitors such as Arimidex® from August 1. Pharmac also announced a review of the ... More >>
NZ Asthmatics Do Have Other Alternatives
Monday, 9 May 2005, 10:15 am | AstraZeneca
Asthma sufferers worried about the part charge for Ventolin®, clogging and bad taste of Salamol™ inhalers, need to know there is another fully funded alternative to both Ventolin® and Salamol™ which has the same efficacy. More >>